AGENUS INC Payments to Acquire Held-to-maturity Securities
AGENUS INC (AGEN) reported Payments to Acquire Held-to-maturity Securities of $14.94 million for the 9-month period ending 2017-09-30, per its 10-Q filed 2018-11-07.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireHeldToMaturitySecurities · last filed 2018-11-07
- AGENUS INC payments to acquire held-to-maturity securities for the quarter ending 2017-09-30 was $0.00, a 100.00% decline year-over-year.
- AGENUS INC payments to acquire held-to-maturity securities for the quarter ending 2017-06-30 was $4.98M, a 66.77% decline year-over-year.
- AGENUS INC payments to acquire held-to-maturity securities for the quarter ending 2017-03-31 was $9.96M, a 71.48% decline year-over-year.
- AGENUS INC payments to acquire held-to-maturity securities for the quarter ending 2016-09-30 was $4.99M, a 56979.53% increase year-over-year.
| Period end | Payments to Acquire Held-to-maturity Securities 3 month | Payments to Acquire Held-to-maturity Securities 6 month | Payments to Acquire Held-to-maturity Securities 9 month |
|---|---|---|---|
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $4.98M derived: sum of 2 quarters · filed 2018-11-07 | $14.94M 10-Q · filed 2018-11-07 |
| 2017-06-30 | $4.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $14.94M 10-Q · filed 2018-08-09 | |
| 2017-03-31 | $9.96M 10-Q · filed 2018-05-10 | ||
| 2016-09-30 | $4.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $19.96M derived: sum of 2 quarters · filed 2017-11-07 | $54.88M 10-Q · filed 2017-11-07 |
| 2016-06-30 | $14.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | $49.90M 10-Q · filed 2017-08-07 | |
| 2016-03-31 | $34.92M 10-Q · filed 2017-05-04 | ||
| 2015-09-30 | $8.74K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $15.01M 10-Q · filed 2016-11-09 | |
| 2015-06-30 | $15.00M 10-Q · filed 2016-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |